Medical experts offer their insights and closing remarks regarding patient feedback for MDS.
James McCloskey, MD
Advertisement
Articles by James McCloskey, MD
Medical experts discuss considerations and patient guidance for oral and IV HMAs.
Medical experts discuss innovations and future directions in treatments for higher-risk MDSMedical experts offer patient perspectives on advantages and disadvantages of using oral HMAs vs injectable HMAs.
Medical experts discuss innovations and future directions in treatments for higher-risk MDS.
Medical experts offer insights on the persistence and effectiveness of HMAs in patients with higher-risk MDS.
Medical experts discuss convenience and efficacy in higher-risk MDS regarding oral vs injectable HMAs.
Medical experts discuss the data gathered from the ASCERTAIN trial.
Medical experts offer insights on the COMMANDS trial findings.
Medical experts discuss risk-based approaches to choosing MDS therapies.
After a brief introduction, medical experts discuss advances in MDS classification and molecular understanding.
Advertisement
Latest Updated Articles
Luspatercept in Lower Risk MDS: Insights on the COMMANDS TrialPublished: September 3rd 2024 | Updated:
- ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS
Published: September 3rd 2024 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Evinacumab-dgnb Approval for Children as Young as 1 Year With HoFH
2
In Primary Care–Oncology Collaboration, the Baton Goes Both Ways
3
FDA Approves Imlunestrant for ER+ and HER2-Negative Breast Cancer
4
Trust and Transparency Key for Leveraging AI to Expand Access to Precision Oncology
5
